ANTROQUINONOL IN AUTOIMMUNE DISORDER
Autoimmune disease is a condition in which your immune system mistakenly attacks your body and is often associated with high levels of inflammation in the body. Antroquinonol, with its interference with the Ras-PI3K-Akt-mTOR pathway, can attenuate cellular levels of NF-κB and TNF-α, which are considered as the important proteins involved in the inflammation pathway. Antroquinonol can also increase the level of Nrf2 and inhibit nitric oxide production, protecting cells via induction of AMPK.
Studies have suggested that Antroquinonol could be a potential therapeutic agent for focal segmental glomerulosclerosis, or FGS, which is a common form of idiopathic nephritic syndrome that represents a therapeutic challenge for its poor response to steroids. Antroquinonol acts so by boosting Nrf2 activation and suppressing NF-κB-dependent inflammatory and TGF-β1-mediated fibrosis pathways in the kidney while protecting the kidney from immunological damages resulting from the disease.
Golden Biotechnology is currently evaluating Antroquinonol in clinical trials for atopic dermatitis and hepatitis B.
View research publications on Antroquinonol in Autoimmune Disease.
For more clinical trial information please visit ClinicalTrials.gov.
- Chang, Jia-Ming, et al. “An extract of Antrodia camphorata mycelia attenuates the progression of nephritis in systemic lupus erythematosus-prone NZB/W F1 mice.” Evidence-Based Complementary and Alternative Medicine 2011 (2011).
- Tsai, Pei-Yi, et al. “Antroquinonol reduces oxidative stress by enhancing the Nrf2 signaling pathway and inhibits inflammation and sclerosis in focal segmental glomerulosclerosis mice.” Free Radical Biology and Medicine 50.11 (2011): 1503-1516.
- Tsai, Pei‐Yi, et al. “Antroquinonol differentially modulates T cell activity and reduces interleukin‐18 production, but enhances Nrf2 activation, in murine accelerated severe lupus nephritis.” Arthritis & Rheumatism 64.1 (2012): 232-242.
- Chiang, Po-Cheng, et al. “Antroquinonol displays anticancer potential against human hepatocellular carcinoma cells: a crucial role of AMPK and mTOR pathways.” Biochemical pharmacology 79.2 (2010): 162-171.